ÂÜÀòÂÒÂ×

Hsiang-Ching Chung began their work experience in 2011 as a Research Assistant at Academia Sinica, Taiwan. They then joined Baylor College of Medicine in 2021 as a Postdoctoral Associate, where they focused on genetic RNAi screens to identify vulnerabilities and resistance mechanisms in triple-negative breast cancer (TNBC). They also worked on understanding cell death mechanisms and developed assays for protein degradation assessment. Currently, in 2022, they are employed as a Scientist at Interline Therapeutics.

Hsiang-Ching Chung completed a Bachelor of Science in Clinical Laboratory Science/Medical Technology/Technologist at National Yang Ming University from 2005 to 2009. Subsequently, they pursued a Master of Science in Oncology and Cancer Biology at National Taiwan University from 2009 to 2011. Finally, between 2013 and 2020, Hsiang-Ching Chung earned a Doctor of Philosophy - PhD in Oncology and Cancer Biology from Baylor College of Medicine.